Evidence map›Paper›PMID 29805502›Full record

ArticleExperimental and therapeutic medicine2018

MicroRNA-216b-3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase/T-LAK-cell-originated protein kinase.

Yaqin Chai, Huijun Xue, Yanmei Wu, Xiaomei Du, Zhuohong Zhang, Yinliang Zhang, Lili Zhang, Shuanbao Zhang, Zhiguo Zhang, Zhiwen Xue

RetractedOpen access · diamondAbstract readRetracted Publication
In one paragraph

Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yaqin ChaiDepartment of Respiratory Medicine, Xi'an XD Group Hospital, Xi'an, Shaanxi 710077, P.R. China.
Huijun XueDepartment of Respiratory Medicine, Xijing Hospital, Xi'an, Shaanxi 710032, P.R. China.
Yanmei WuDepartment of Respiratory Medicine, Xi'an XD Group Hospital, Xi'an, Shaanxi 710077, P.R. China.
Xiaomei DuDepartment of Respiratory Medicine, Xi'an XD Group Hospital, Xi'an, Shaanxi 710077, P.R. China.
Zhuohong ZhangDepartment of Respiratory Medicine, Xi'an XD Group Hospital, Xi'an, Shaanxi 710077, P.R. China.
Yinliang ZhangDepartment of Respiratory Medicine, Xi'an XD Group Hospital, Xi'an, Shaanxi 710077, P.R. China.
Lili ZhangDepartment of Respiratory Medicine, Xi'an XD Group Hospital, Xi'an, Shaanxi 710077, P.R. China.
Shuanbao ZhangDepartment of Respiratory Medicine, Xi'an XD Group Hospital, Xi'an, Shaanxi 710077, P.R. China.
Zhiguo ZhangDepartment of Respiratory Medicine, Xi'an XD Group Hospital, Xi'an, Shaanxi 710077, P.R. China.
Zhiwen XueDepartment of Respiratory Medicine, Xi'an XD Group Hospital, Xi'an, Shaanxi 710077, P.R. China.
China XD Group (China) · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous studies have reported that microRNA (miR)-216b, as a tumor suppressor, is downregulated in a variety of cancer types. PDZ binding kinase (PBK)/T-LAK-cell-originated protein kinase (TOPK) is highly expressed in various types of human cancer, including lung cancer. The expression of miR-216b-3p and its potential roles in lung adenocarcinoma are still unclear and no research has been conducted into the association between miR-216b-3p and PBK/TOPK. Thus, the present study aimed to investigate the expression and role of miR-216b-3p in lung adenocarcinoma and to explore whether PBK/TOPK is involved in the underlying mechanisms of lung adenocarcinoma. The expression of miR-216b-3p in lung adenocarcinoma cell lines was detected. PBK/TOPK protein expression levels were also determined within lung adenocarcinoma cell lines. To investigate the association between miR-216b-3p and PBK/TOPK, TargetScan analysis was performed; PBK was predicted to be a potential target gene of miR-216b-3p, and a dual luciferase reporter assay was applied to confirm this prediction. To investigate the role of miR-216b-3p in lung adenocarcinoma, a lung adenocarcinoma cell line (GLC-82) was transfected with miR-216b-3p mimic or its negative control. An MTT assay was applied to detect cell proliferation, and cell apoptosis was analyzed by flow cytometry. Western blot analysis was performed to determine the protein expression levels of associated proteins. The results of the present study suggested that miR-216b-3p was downregulated in lung adenocarcinoma cell lines and PBK/TOPK was highly expressed in lung adenocarcinoma cells. miR-216b-3p directly targets PBK and negatively regulates its expression. miR-216b-3p overexpression may inhibit GLC-82 cell proliferation and induce cell apoptosis. In addition, miR-216b-3p overexpression may increase p53 and p21 expression, and prevent p38 MAPK activation. These effects on GLC-82 cells caused by miR-216b-3p overexpression may be eliminated by PBK/TOPK overexpression. In conclusion, miR-216b-3p was downregulated in lung adenocarcinoma and may function as a tumor suppressor by inhibiting cell growth via regulating PBK/TOPK expression.

Indexed as

cell growthlung adenocarcinomamicroRNA-216b-3pPDZ binding kinase/T-LAK-cell-originated protein kinase

Identifiers

PMID29805502
PMCPMC5952093
OpenAlexW2795686185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.